Clinical trial · Interventional
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn whether tomotherapy will be able to deliver higher radiation doses safely to the tumor while sparing the surrounding normal tissue.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Functional MRI imaging and tomotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- determine tumor response and pattern of failure using functional MRI imaging
- timeFrame
- Study completion
- measure
- time to disease progression
- timeFrame
- Study completion
Secondary outcomes (3)
- measure
- distinguish residual tumor from treatment-related necrosis
- timeFrame
- study completion
- measure
- survival
- measure
- acute late toxicity of tomotherapy and hypofractionation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed glioblastoma multiforme * Ages 18-65 * Karnofsky Performance Scale (KPS) equal to or less than 70 * Minimal neurological deficit * Eligible for concurrent temozolomide chemotherapy Exclusion Criteria: * Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer
References
Publications (0)
Data not yet available